Estrogen and progesterone receptor-negative breast cancer disproportionately affects young women and African Americans, has a poor prognosis, and lacks an effective chemoprevention agent. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as "statins," are appealing candidate agents for breast cancer chemoprevention because of their demonstrated safety after decades of widespread use. In preclinical studies, statins inhibit multiple cancer-associated pathways in both hormone receptor (HR)-negative and HR-positive cell lines. Epidemiologic studies of statins and breast cancer show inconsistent results, with some suggesting a reduction in HR-negative breast cancer incidence in lipophilic statin users. However, large meta-analyses show no association between statin use and overall risk of breast cancer, although most did not evaluate tumor HR status. Multiple phase 1 and 2 prevention studies of statins for breast cancer risk reduction are ongoing. If results are promising, they may justify a randomized trial of statins for breast cancer chemoprevention, with a focus on HR-negative disease.
Introduction
Over the past decade, randomized trials have shown that medications, specifi cally the selective estrogen response modulators (SERMs), tamoxifen and raloxifene, may reduce risk of developing breast cancer. However, SERMs prevent the development of estrogen receptorand progesterone receptor-positive (hormone receptor [HR]-positive) breast cancer only, without reducing risk of HR-negative disease [1] [2] [3] . Approximately 20% of breast cancers in the United States are HR-negative, based on data from the Surveillance, Epidemiology, and End Results (SEER) registry [4] . However, recent analyses of the Carolina Breast Cancer Study, California Cancer Registry, and other cohorts have found that nearly 40% of breast cancers in young women and African Americans are HR-negative. These cancers often have higher tumor grade and worse survival [5] [6] [7] . Consequently, there is an important and unmet need for prevention of HR-negative breast cancer.
Multiple drug classes are under investigation for their potential ability to prevent HR-negative breast cancer by targeting nonendocrine pathways, including retinoids, selective cyclo-oxygenase-2 inhibitors, and tyrosine kinase inhibitors [8] . However, chemoprevention requires treating cancer-free people over a period of years for a disease they may never develop. Therefore, any candidate agent must be very safe and well tolerated if it is to prove acceptable to healthy patients. These requirements have led investigators to reevaluate medications that have a history of widespread, successful use for noncancer indications, and to focus specifi cally on statins. Statins have been used in the general US population since 1987 for treatment of hypercholesterolemia [9] . Buchwald [10] initially proposed that cholesterol inhibition could prevent carcinogenesis, after he observed inhibition of tumor growth in cell culture and in vivo experiments. Subsequent preclinical and epidemiologic studies suggested potential effi cacy for statins against HR-negative breast cancer and increased enthusiasm for targeted chemoprevention studies. This article reviews evidence from preclinical, epidemiologic, and intervention studies that have prompted consideration of statins for chemoprevention of HR-negative breast cancer. Ongoing trials designed to test their effi cacy for this purpose are also summarized.
Preclinical Studies

General statin mechanisms
Statins are small-molecule inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes conversion of HMG-CoA to mevalonate and enables subsequent cholesterol synthesis. Despite a shared I Vinayak and Kurian I 149 mechanism, individual statins differ signifi cantly in their structure, pharmacodynamic profi le, and lipid-modifying effi cacy, infl uencing water solubility, absorption, metabolism, and excretion [11] . Atorvastatin, simvastatin, lovastatin, fl uvastatin, and cerivastatin are categorized as lipophilic statins, whereas pravastatin and rosuvastatin are categorized as hydrophilic. Bioavailability varies signifi cantly among the statins; in general, hydrophilic statins have reduced peripheral tissue uptake [11] .
Statins as a drug class inhibit the rate-limiting step in the HMG-CoA reductase pathway, which results in decreased levels of mevalonate and downstream products, including lipid isoprenoid intermediates, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) [12] . These isoprenoid intermediates provide lipid attachments for intracellular G-proteins, such as Ras and Rho, which must undergo post-translational prenylation by FFP or GGPP to enable their translocation from cytoplasm to cell membrane [12] . Statin inhibition of mevalonate synthesis impedes cellular pathways, such as protein synthesis and cell-cycle progression, which are critical for cancer cell growth and survival [12] .
Beyond this basic mechanism, statins appear to exert pleiotropic effects, including anti-infl ammatory, proapoptotic, growth inhibitory, and prodifferentiation properties on malignant cells of diverse origins, including the breast [13] . Despite their plethora of cellular actions, there is no obvious single mechanism by which statins may prevent breast cancer development. There have been multiple studies evaluating the in vitro and in vivo effects of statins, both lipophilic and hydrophilic statin subtypes, including several focused specifi cally on breast cancer-associated pathways. We review these preclinical studies according to the potential anticancer mechanism investigated.
Proliferation and apoptosis
Statins mediate growth inhibition through multiple pathways, in both HR-negative and HR-positive cell lines: they reduce cell proliferation by promoting G1 cell cycle arrest [14] . Campbell et al. [15•] reported that statins alter regulation of cell survival and proliferation by suppressing the mitogen-activated protein kinase pathway, activating nuclear factor κ B, and increasing synthesis of p21, a cyclin-dependent kinase inhibitor. Growth inhibition was most marked in HR-negative breast cancer cells exposed to lipophilic statins, in vitro and in vivo. By contrast, pravastatin, a hydrophilic statin, did not inhibit growth of any breast cancer cell line, regardless of HR status [15•]. Mueck et al. [16] studied fi ve different statins in HR-positive and HR-negative cell lines. Statins inhibited the growth of HR-negative more potently than HR-positive cell lines, and pravastatin again showed no effect. Independent of the HMG-CoA pathway and HR status, statins can also reduce cell proliferation via proteosome inhibition [17] , and induce apoptosis through a nitric oxide and arginine-dependent pathway [18] and via the c-Jun NH2-terminal kinase pathway [19] .
Angiogenesis
Statins have been shown to promote and inhibit angiogenesis. Their blockade of the mevalonate pathway appears to inhibit tumor-induced angiogenesis [20, 21] ; cerivastatin decreases endothelial cell locomotion, an effect that can be reversed by addition of GGPP [20] . Statins also affect other antiangiogenesis pathways. Lovastatin suppresses vascular endothelial growth factor production in transformed breast cancer cell lines, and its effect is potentiated by combination with tumor necrosis factor α [21]. In contrast, one study found that simvastatin may promote angiogenesis by activating protein kinase Akt, and increasing nitric oxide release [22] .
Tumor metastasis
Cellular mechanisms such as adhesion, migration, and proteolysis are involved in tumor organization and metastasis. Lovastatin inhibits metastasis in murine mammary tumor models, and blocks tumor cell attachment and cell migration in a highly invasive cell line [23] . Cerivastatin inhibits cell invasiveness by reducing synthesis of phenylated RhoA, a G-protein involved in regulation of the actin cytoskeleton [24] . Statins inhibit migration of breast cancer cells by blocking synthesis of oxysterol, a lipid mediator of migration derived from the mevalonate pathway [25] . An alternate mechanism involves inhibition of matrix metalloproteinases (MMPs), which enable tumor growth, invasion, and metastasis by degrading the extracellular matrix. Cerivastatin blocks RhoA cell-signaling pathways, reducing expression of urokinase and MMPs [13, 24] .
Recent studies suggest a novel mechanism for statins' inhibition of MMP expression, dependent on caveolin, a cholesterol-binding protein. These proteins reside in caveolae, cholesterol-rich infoldings of the plasma membrane that are involved in signal transduction and vesicular traffi cking and appear to act as tumor suppressors [13] . In breast cancer tissue and in vivo studies, caveolin-1 expression inhibits breast cancer growth and metastasis. When the caveolin-1 gene is disrupted, tumor formation and metastasis result [26, 27] . The expression of caveolin-1 and caveolin-2 is associated with the HR-negative, basal-like breast cancer phenotype [28] . Caveolin gene and protein expression appears to differ by statin lipophilicity. In human smooth muscle cells, lipophilic statins stimulate caveolin-1 expression, but hydrophilic statins have no effect [29] . This newly reported caveolin-related mechanism is a high priority for further study because it may in part explain the differences according to statin and tumor subtype observed in observational studies.
Observational Studies of Statins and Breast Cancer in Humans
A potential association between statin treatment and breast cancer risk was initially evaluated in secondary safety analyses of randomized trials of statins for hyperlipidemia
